

November 3rd, 2022

Dear NAM Action Collaborative on Decarbonizing the U.S. Health Sector Members,

We seek to join the National Academy of Medicine Action Collaborative on Decarbonizing the U.S. Health Sector (Climate Collaborative) as a Network Organization. We commit to three priority areas: Health Care Delivery; Health Care Supply Chain and Infrastructure; and Policy, Financing and Metrics. We believe that our experience can provide important insights to advance your efforts.

Chiesi, a global biopharmaceutical company, is driven by our desire to increase the quality of life for patients, their families and their communities. From the millions of people suffering from chronic respiratory diseases, to ultra-rare genetic disorders, with only a few thousand known cases, we focus on where we can make the biggest difference in the life of a patient.

Supporting the most vulnerable among us gives us a deep perspective into the fragility of life and into the inseparable connection between human health and the health of the society and the environment around us. For this reason, we make conscious choices aiming to advance the well-being of our communities and acting as a force for good.

We are proud that we have become a certified Benefit Corporation, holding ourselves accountable to high standards of social and environmental impact. Our recent recertification ([link](#)) recognized our sustainability progress across our operations and actions and in our impact on society.

An example of how a pharmaceutical company can improve human health and the health of the planet is what we have been able to do with our pressurized metered-dose inhalers (pMDIs) for asthma and COPD. Chiesi committed €350 million to develop a new environment-friendly solution by replacing the current propellant in the inhaler with an innovative low environmental impact propellant, reducing the carbon footprint of our pMDIs by nearly 90% by 2025.

Additionally:

- We are committed to becoming net zero by 2030 on direct emissions and emissions coming from purchased electricity and heat and by 2035 on emissions in our value chain and transparently reporting progress at [Actionoverwords.org](https://www.actionoverwords.org)

(Additional information on our Annual&Sustainability Report: <https://chiesireport.com/home/>).

- In UK we launched a first-of-its-kind inhaler recycling program through which aluminum canisters are reused, plastic components are returned to the supply chain, and any remaining propellant gas is reused in electrical appliances.
- Our Sustainable Chemistry Policy ensures that we manage chemical substances used for research and manufacturing activities with safeguards for the environment.
- We are committed to reinforce and improve the environmental sustainability profile of Chiesi's therapies, by assessing the environmental sustainability of our products in accordance with circular economy principles.
- We co-created with our suppliers the "Code of Interdependence", a set of common values through which Chiesi aims to collaborate only with companies and partners that share its commitment to sustainability and positively change the entire value chain.

If it is possible for Chiesi as a global, complex, and innovative company to promote a conscious and sustainable way of doing business, by fostering a collaborative dialogue among stakeholders, it should be possible for many others. Shared responsibility with governmental bodies, regulators, payers, healthcare institutions, other pharmaceutical companies, and advocates is essential to advancing progress.

We commit to sharing responsibility and offer guidance to the Climate Collaborative as a Network Organization.

Sincerely,

Maria Paola Chiesi

Director Shared Valued & Sustainability